Can Clopidogrel reduce thrombotic risks in patients with metabolic syndrome, and how does it compare to other antiplatelet medications?
Sahil KapoorExplorer
Sign Up to our social questions and Answers Engine to ask questions, answer people’s questions, and connect with other people.
Please briefly explain why you feel this question should be reported.
Please briefly explain why you feel this answer should be reported.
Please briefly explain why you feel this user should be reported.
Clopidogrel can reduce thrombotic risks in patients with metabolic syndrome. It’s less potent than newer agents like ticagrelor but offers fewer side effects than prasugrel.